FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients were randomised to either placebo, eptifibatide 180 microgram/kg bolus followed by a 2.0 microgram/kg/min infusion (180/2.0), or eptifibatide 180 microgram/kg bolus followed by a 1.3 microgram/kg/min infusion (180/1.3).
Icelandic: innrennsli (180/2,0), eða 180 míkróg/kg hleðsluskammt af eptifibatíð fylgt eftir með 1,3 míkróg/kg/mín. innrennsli (180/1,3).
English: There was no indication of severe adverse reactions associated with administration of accidental large bolus doses, rapid infusion reported as overdose or large cumulative doses.
Icelandic: Engin merki voru um alvarlegar aukaverkanir sem tengdust of stórum skammti gefnum af slysni, hröðu innrennsli eða stórum uppsöfnuðum skammti.
English: Before using, the vial contents should be inspected.
Icelandic: Áður en lyfið er notað verður að athuga vel innihald hettuglassins.
English: Early routine eptifibatide in this high-risk NSTE-ACS optimally-treated population who were managed with an invasive strategy did not result in a statistically significant reduction in the composite primary endpoint of rate of death, MI, RI-UR, and TBO within 96 hours compared with a regimen of delayed provisional eptifibatide (9.3 % in early eptifibatide patients vs. 10.0 % in patients assigned to delayed provisional eptifibatide; odds ratio=0.920; 95 % CI=0.802-1.055; p=0.234).
Icelandic: samanborið við meðferðaráætlun sem fól í sér síðbúna notkun eptifibatíðs eftir þörfum (9,3% hjá sjúklingum sem fengu eptifibatíð snemma á móti 10,0% hjá sjúklingum við síðbúna notkun eptifibatíðs eftir þörfum; líkindahlutfall=0,920; 95% CI=0,802-1,055; p=0,234).
English: There is limited therapeutic experience with eptifibatide in patients for whom thrombolytic therapy is generally indicated (e.g. acute transmural myocardial infarction with new pathological Q-waves or elevated ST-segments or left bundle branch block in the ECG).
Icelandic: Læknisfræðileg reynsla af verkun eptifibatíðs er takmörkuð hjá þeim sjúklingum sem almennt er mælt með að gangist undir segaleysandi meðferð (þ.e.a.s. sjúklingum með brátt þverveggjahjartadrep með nýjar vefjameinafræðilegar Q-bylgjur eða hækkaða ST-geira eða vinstra greinrof í ECG).
English: Each ml of solution for injection contains 2 mg of eptifibatide.
Icelandic: Hver ml af stungulyfi, lausn inniheldur 2 mg af eptifibatíði.
English: Clinical Trials
Icelandic: Klínískar rannsóknir
English: Eptifibatide inhibits platelet aggregation in a dose- and concentration-dependent manner as demonstrated by ex vivo platelet aggregation using adenosine diphosphate (ADP) and other agonists to induce platelet aggregation.
Icelandic: Eptifibatíð hindrar samloðun blóðflagna og eru áhrifin háð skömmtum og styrk lyfsins eins og kemur fram í blóðflagnasamloðun ex vivo með notkun adenosine difosfats (ADP) og annarra agonista sem valda samloðun blóðflagna.
English: Eptifibatide Accord solution for injection must be used in conjunction with Eptifibatide Accord solution for infusion.
Icelandic: Eptifibatide Accord innrennslislyf, lausn verður að nota ásamt Eptifibatide Accord stungulyfi, lausn.
English: − severe reduction in the number of platelets (blood cells necessary for blood clotting).
Icelandic: - alvarleg fækkun blóðflagna (blóðkorn nauðsynleg fyrir blóðstorknun).
English: Eptifibatide -treated patients who had a prothrombin time (PT) > 14.5 seconds and received warfarin concomitantly did not appear to be at an increased risk of bleeding.
Icelandic: Blæðingarhætta virtist ekki aukast hjá sjúklingum í meðferð með eptifibatíði, sem höfðu prótrombín-tímann > 14,5 sekúndur og fengu warfarín samtímis.
English: The decision to use platelet transfusions should be based upon clinical judgment on an individual basis.
Icelandic: Ákvörðun um að hefja gjöf á blóðflögum skal tekin á faglegum grunni með tilliti til hvers einstaklings fyrir sig.
English: Results on the primary endpoint were principally attributed to the occurrence of myocardial infarction.
Icelandic: Niðurstöður varðandi meginendapunktinn má einkum rekja til þess að hjartadrep kemur fyrir.
English: Each ml of solution for infusion contains 0.75 mg of eptifibatide.
Icelandic: Hver ml af innrennslislyfi, lausn inniheldur 0,75 mg af eptifibatíði.
English: Data are limited on the use of eptifibatide in patients receiving thrombolytic agents.
Icelandic: Takmarkaðar upplýsingar eru til um notkun eptifibatíðs hjá sjúklingum sem eru á segaleysandi lyfjum.
English: Very common Bleeding (major and minor bleeding including femoral artery access, CABGrelated, gastrointestinal, genitourinary, retroperitoneal, intracranial, haematemesis, haematuria, oral/oropharyngeal, haemoglobin/haematocrit decreased and other).
Icelandic: Mjög algengar Blæðingar (meiri- og minniháttar blæðingar þ.m.t. á stungustað í lærleggsslagæð, CABG-tengdar, í meltingarfærum, þvag- og kynfærum, bakskinu (retroperitoneal), innan höfuðkúpu, blóðuppköst, blóðmiga, í munni/munnholi, lækkun blóðrauða/blóðkornaskila og fleiri).
English: ESPRIT: This was a double-blind, multicentre, randomized, parallel-group, placebo-controlled trial evaluating the safety and efficacy of eptifibatide therapy in patients scheduled to undergo nonemergent percutaneous coronary intervention (PCI) with stent implantation.
Icelandic: Þetta var tvíblind, fjölsetra, slembuð rannsókn með samhliða hópum og samanburð við lyfleysu til að leggja mat á öryggi og verkun meðferðar með eptifibatíði hjá sjúklingum sem fara í kransæðavíkkun (PCI) með innsetningu stoðnets í skipulagðri (non-emergent) aðgerð.
English: When followed by a 2.0 microgram/kg/min continuous infusion, this regimen produces a > 80 % inhibition of ADP-induced ex vivo platelet aggregation, at physiologic calcium concentrations, in more than 80 % of patients.
Icelandic: 80 % hindrun á ADP-hvattri blóðflagnasamloðun ex vivo, við eðlilegan kalkstyrk, í meira en 80 % sjúklinga.
English: In the same population, plasma elimination half-life is approximately 2.5 hours, plasma clearance 55 to 80 ml/kg/hr and volume of distribution of approximately 185 to 260 ml/kg.
Icelandic: Próteinbinding í plasma hjá mönnum er u.þ.b. 25 %. Í sama rannsóknarhópi var helmingunartími í plasma u.þ.b. 2,5 klukkustundir, plasmaúthreinsun 55-80 ml/kg/klst. og dreifingarrúmmálið u.þ.b. 185-260 ml/kg.
English: Monitoring of laboratory values
Icelandic: Eftirlit með rannsóknarniðurstöðum
English: Use in patients with more severe renal impairment is contraindicated (see section 4.3).
Icelandic: Ekki má nota lyfið hjá sjúklingum með verulega skerta nýrnastarfsemi (sjá kafla 4.3).
English: One 100 ml vial contains 75 mg of eptifibatide.
Icelandic: Eitt 100 ml hettuglas inniheldur 75 mg af eptifibatíði.
English: In patients with moderate to severe renal insufficiency (creatinine clearance < 50 ml/min), the clearance of eptifibatide is reduced by approximately 50 % and steady-state plasma levels are approximately doubled.
Icelandic: Hjá sjúklingum með miðlungs eða mjög mikla skerðingu á nýrnastarfsemi (kreatínínúthreinsun < 50 ml/mín), minnkar útskilnaður eptifibatíðs um u.þ.b. 50% og plasmaþéttni við jafnvægi u.þ.b. tvöfaldast.
English: The experience in humans with overdose of eptifibatide is extremely limited.
Icelandic: Mjög takmörkuð reynsla er af ofskömmtun eptifibatíðs hjá mönnum.
English: Eptifibatide Accord must not be used to treat patients with: - hypersensitivity to the active substance or to any of the excipients listed in section 6.1 - evidence of gastrointestinal bleeding, gross genitourinary bleeding or other active abnormal bleeding within the previous 30 days of treatment - history of stroke within 30 days or any history of haemorrhagic stroke - known history of intracranial disease (neoplasm, arteriovenous malformation, aneurysm) - major surgery or severe trauma within past 6 weeks - a history of bleeding diathesis - thrombocytopenia (< 100,000 cells/mm3) - prothrombin time > 1.2 times control, or International Normalized Ratio (INR) ≥ 2.0 - severe hypertension (systolic blood pressure > 200 mm Hg or diastolic blood pressure
Icelandic: 30 daga eða öll fyrri tilfelli um slag vegna blæðinga - ef vitað er um sjúkdóm í höfði (æxli, afbrigðilegar slag- og bláæðar, slagæðagúlpur) - stóraðgerð eða alvarlegir áverkar á síðastliðnum 6 vikum - saga um blæðingasjúkdómshneigð - blóðflagnafæð (< 100.000 frumur/mm3) - prótrombíntími > 1,2 föld viðmiðun eða INR ≥ 2,0 - alvarlegur háþrýstingur (slagbilsþrýstingur
English: It is contraindicated in patients with clinically significant hepatic impairment.
Icelandic: Ekki má nota lyfið hjá sjúklingum með klínískt mikilvæga skerðingu á lifrarstarfsemi.
English: Eptifibatide Accord 2 mg/ml solution for injection eptifibatide
Icelandic: Eptifibatide Accord 2 mg/ml stungulyf, lausn eptifibatíð
English: Keep this medicine out of the sight and reach of children Do not use this medicine after the expiry date which is stated on the carton and the vial after (EXP).
Icelandic: Ekki skal nota lyfið eftir fyrningardagsetningu sem tilgreind er á öskjunni og hettuglasinu á eftir (EXP).
English: Eptifibatide Accord should not be used during pregnancy unless clearly necessary.
Icelandic: Ekki skal nota Eptifibatide Accord á meðgöngu nema brýna nauðsyn beri til.
English: One 10 ml vial contains 20 mg of eptifibatide.
Icelandic: Eitt 10 ml hettuglas inniheldur 20 mg af eptifibatíði.
English: In an acute myocardial infarction study involving 181 patients, eptifibatide (in regimens up to a bolus injection of 180 microgram/kg, followed by an infusion up to 2 microgram/kg/min for up to 72 hours) was administered concomitantly with streptokinase (1.5 million units over 60 minutes).
Icelandic: Í rannsóknum á bráðu hjartadrepi þar sem 181 sjúklingur tók þátt, var eptifibatíð (meðferðaráætlun með hleðsluskammt allt að 180 míkróg/kg, fylgt eftir með innrennsli allt að 2 míkróg/kg/mín.
English: Cardiac arrest, ventricular fibrillation, ventricular tachycardia, congestive heart failure, atrioventricular block, atrial fibrillation.
Icelandic: Hjartastopp, sleglatif, sleglahraðtaktur, blóðríkishjartabilun, gáttaleglarof, gáttatif.
English: Solution for injection 1 vial of 10 ml
Icelandic: Stungulyf, lausn 1 hettuglas með 10 ml
English: Keep this medicine out of the sight and reach of children Do not use this medicine after the expiry date which is stated on the carton and the vial after EXP.
Icelandic: Ekki skal nota lyfið eftir fyrningardagsetningu sem tilgreind er á öskjunni og hettuglasinu á eftir EXP.
English: − fatal bleeding.
Icelandic: Blóðflagnafæð.
English: Administer with caution to patients with hepatic impairment in whom coagulation could be affected (see section 4.3, prothrombin time).
Icelandic: Gæta skal varúðar við gjöf lyfsins hjá sjúklingum með skerta lifrarstarfsemi þar sem blóðstorknunin getur verið óeðlileg hjá þeim (sjá kafla 4.3, prótrombíntími).
English: With delayed provisional eptifibatide administration, the TIMI major events were 1.4 % vs 2.0 % in patients who received reduced dose and standard dose respectively (p=0.54).There were no notable differences observed with GUSTO severe bleeding rates.
Icelandic: Með gjöf eptifibatíðs seinna eftir þörfum var tíðni verulegra blæðinga (TIMI) hjá sjúklingum sem fengu lækkaðan skammt 1,4% samanborið við 2,0% hjá sjúklingum sem fengu venjulegan skammt (p=0,54).
English: The primary endpoint event rate was 11.9 % in patients who received a reduced dose (1microgram/kg/min) vs 11.2 % in patients who received the standard dose (2 microgram/kg/min) when eptifibatide was administered in the early routine fashion (p=0.81).
Icelandic: samanborið við 11,2% hjá sjúklingum sem fengu hefðbundinn skammt (2 míkróg/kg/mín) þegar eptifibatíð var gefið snemma (p=0,81).
English: Excipients: Citric acid monohydrate, sodium hydroxide, water for injections.
Icelandic: Sítrónusýrueinhýdrat, natríumhýdroxíð, vatn fyrir stungulyf.
English: Before infusion of Eptifibatide Accord, the following laboratory tests are recommended to identify preexisting haemostatic abnormalities: prothrombin time (PT) and aPTT, serum creatinine, platelet count, haemoglobin and haematocrit levels.
Icelandic: Áður en til innrennslis Eptifibatide Accord kemur, er mælt með að rannsaka eftirfarandi þætti til að sjá hvort starfsemi blóðsins er eðlileg: prótrombíntímann (PT) og virkan hlutfallslegan prótrombíntíma (aPTT), kreatínín í blóði, fjölda blóðflagna, blóðrauða og blóðkornaskil.
English: In patients with moderate renal impairment (creatinine clearance ≥ 30 - < 50 ml/min), an intravenous bolus of 180 microgram/kg should be administered followed by a continuous infusion dose of 1.0 microgram/kg/min for the duration of therapy.
Icelandic: Sjúklingum með skerta nýrnastarfsemi (kreatínín úthreinsun ≥ 30 - < 50 ml/mín), skal gefa 180 míkróg/kg hleðsluskammt í æð og í framhaldi af því 1,0 míkróg/kg/mín.
English: Breast-feeding
Icelandic: PURSUIT-rannsóknin
English: These may affect up to 1 in 10,000 people - serious bleeding (for example, bleeding inside the abdomen, inside the brain, and into the lungs).
Icelandic: Aukaverkanir sem koma örsjaldan fyrir Geta komið fyrir hjá allt að1 af hverjum 10.000 einstaklingum - alvarleg blæðing (til dæmis blæðing í kviðarholi, í heila eða í lungum).
English: Eptifibatide Accord 0.75 mg/ml solution for infusion eptifibatide
Icelandic: Eptifibatide Accord 0,75 mg/ml innrennslislyf, lausn eptifibatíð
English: One 100 ml Type I glass vial, closed with a butyl rubber stopper and sealed with a flip-off aluminium seal.
Icelandic: Eitt 100 ml hettuglas úr gleri af gerð I, með tappa úr bútýlgúmmíi og innsiglað með smelluinnsigli úr áli.
English: All potential bleeding sites, (e.g., catheter insertion sites; arterial, venous, or needle puncture sites; cutdown sites; gastrointestinal and genitourinary tracts) must be observed carefully.
Icelandic: Athuga þarf vel alla hugsanlega blæðingarstaði (t.d. þar sem æðalegg er komið fyrir, í slagæð, bláæð, eða nálarstungustað, skurðstað, meltingarfæri, þvag- og kynfæri).
English: For a 2.0 microgram/kg/min infusion, mean steady-state plasma eptifibatide concentrations range from 1.5 to 2.2 microgram/ml in patients with coronary artery disease.
Icelandic: er plasmaþéttni eptifibatíðs við jafnvægi á bilinu 1,5 til 2,2 míkróg/ml hjá sjúklingum með kransæðasjúkdóma.
English: 2.7 % of patients who received a reduced dose (1microgram/kg/min) vs 4.2 % of patients who received the standard dose (2 microgram/kg/min) when eptifibatide was administered in the early routine fashion (p=0.36).
Icelandic: samanborið við 4,2% sjúklinga sem fengu venjulegan skammt (2 míkróg/kg/mín.) þegar eptifibatíð var gefið snemma (p=0,36).
English: This study was a 726-center, 27-country, double-blind, randomised, placebo-controlled study in 10,948 patients presenting with UA or NQMI.
Icelandic: Þessi rannsókn sem var tvíblind, slembiröðuð með samanburði við lyfleysu var framkvæmd á 10.948 sjúklingum með hvikula hjaraöng eða hjartadrep án Q-bylgju frá 726 mismunandi rannsóknarstöðum í 27 löndum.
English: Before using, inspect the vial contents.
Icelandic: Fyrir notkun, þarf að athuga innihald hettuglassins.
English: The recommended dose is 180 microgram/kg administered as a bolus (rapid intravenous injection), followed by an infusion (drip solution) of 2 microgram/kg/minute for up to 72 hours.
Icelandic: Ráðlagður skammtur er 180 míkróg/kg gefinn sem hleðsluskammtur (hröð inngjöf í æð), og fylgt eftir með innrennsli (sídreypi) á 2 míkróg/kg/mín.
English: One 10 ml Type I glass vial, closed with a butyl rubber stopper and sealed with a flip-off aluminium seal.
Icelandic: Eitt 10 ml hettuglas úr gleri af gerð I, með tappa úr bútýlgúmmíi og innsiglað með smelluinnsigli úr áli.
English: These are absolute reporting frequencies without taking into account placebo rates.
Icelandic: Þetta er tíðni allra aukaverkana sem greint var frá án þess að tekið sé tillit til tíðni hjá lyfleysu.
English: There are no adequate data from the use of eptifibatide in pregnant women.
Icelandic: Ekki liggja fyrir neinar fullnægjandi upplýsingar um notkun eptifibatíðs á meðgöngu.
English: > 110 mm Hg on antihypertensive therapy) - severe renal impairment (creatinine clearance < 30 ml/min) or dependency on renal dialysis - clinically significant hepatic impairment - concomitant or planned administration of another parenteral glycoprotein (GP) IIb/IIIa inhibitor
Icelandic: Hg á meðan á háþrýstingslyfjameðferð stendur) - verulega skert nýrnastarfsemi (kreatínínúthreinsun < 30 ml/mín) eða ef sjúklingur er háður blóðskilun - klínískt marktæk skerðing á lifrarstarfsemi - samtímis eða áætluð gjöf annarra glýkóprótein (GP)-IIb/IIIa-hemla til inndælingar
English: Patients were managed according to the usual standards of the investigational site; frequencies of angiography, PCI and CABG therefore differed widely from site to site and from country to country.
Icelandic: Tíðni æðamyndatöku, kransæðavíkkunar og hjáveituaðgerðar var því mjög mismundandi eftir stöðum og löndum.
English: Distrobution
Icelandic: LYFJAFORM
English: Administration of eptifibatide is associated with an increase in major and minor bleeding as classified by the criteria of the TIMI study group.
Icelandic: Gjöf eptifibatíðs tengist aukningu meiri- og minniháttar blæðinga flokkuðum eftir staðli TIMIrannsóknarhópsins.
English: Solution for infusion.
Icelandic: Vatn fyrir stungulyf.
English: What Eptifibatide Accord looks like and contents of the pack
Icelandic: Lýsing á útliti Eptifibatide Accord og pakkningastærðir
English: How to store Eptifibatide Accord
Icelandic: á Eptifibatide Accord
English: PURSUIT: This was a randomized, double-blind evaluation of the efficacy and safety of eptifibatide versus placebo for reducing mortality and myocardial (re)infarction in patients with unstable angina or non-Q-wave myocardial infarction.
Icelandic: Þetta var slembað, tvíblint mat á verkun og öryggi eptifibatíðs með samanburði við lyfleysu til að lækka dánartíðni og tíðni (endurkomu) hjartadreps hjá sjúklingum með hvikula hjartaöng eða hjartadrep án Q-bylgju.
English: Solution for infusion 1 vial of 100 ml
Icelandic: Innrennslislyf, lausn 1 hettuglas með 100 ml
English: - anaemia (decreased number of red blood cells).
Icelandic: - blóðleysi (fækkun rauðra blóðkorna).
English: Eptifibatide Accord 2 mg/ml solution for injection
Icelandic: Eptifibatide Accord 2 mg/ml:
English: In healthy subjects, renal excretion accounted for approximately 50 % of total body clearance; approximately 50 % of the amount cleared is excreted unchanged.
Icelandic: Hjá heilbrigðum einstaklingum er nýrnaútskilnaður talinn vera u.þ.b. 50% af heildarútskilnaði lyfsins; u.þ.b. 50% þess skilst út í óbreyttu formi.
English: In patients with moderate renal impairment, (creatinine clearance 30 - 50 ml/min) 100 % inhibition was achieved at 24 hours following administration of 2 microgram/kg/min.
Icelandic: Hjá sjúklingum með miðlungs skerta nýrnastarfsemi (kreatínínúthreinsun 30-50 ml/mín.) náðist 100% hindrun 24 klst.
English: One vial of 100 ml of solution for infusion contains 75 mg of eptifibatide.
Icelandic: Eitt hettuglas með 100 ml af innrennslislyfi, lausn, inniheldur 75 mg af eptifibatíði.
English: Eptifibatide Accord 0.75 mg/ml solution for infusion
Icelandic: - Eptifibatide Accord 0,75 mg/ml:
English: However, protection of Eptifibatide Accord solution from light is not necessary during administration.
Icelandic: Ekki er þó nauðsynlegt að verja Eptifibatide Accord ljósi meðan það er gefið.
English: Changes during eptifibatide treatment result from its known pharmacological action, i.e., inhibition of platelet aggregation.
Icelandic: Breytingar sem verða meðan á eptifibatíðmeðferð stendur eru vegna lyfjafræðilegrar verkunar lyfsins, þ.e.a.s. hindrunar á samloðun blóðflagna.
English: Common side effects These may affect up to 1 in 10 people - inflammation of a vein.
Icelandic: Geta komið fyrir hjá allt að 1 af hverjum 10 einstaklingum - bláæðabólga.
English: Fatal bleeding (the majority involved central and peripheral nervous system disorders: cerebral or intracranial haemorrhages); pulmonary haemorrhage, acute profound thrombocytopenia, haematoma.
Icelandic: Lífshættulegar blæðingar (flestar tengdust kvillum í mið- eða úttaugakerfinu: blæðingar í heila eða innan höfuðkúpu); blæðing í lungum, bráð alvarleg blóðflagnafæð, margúll.
English: Protection of Eptifibatide Accord solution from light is not necessary during administration.
Icelandic: Ekki er þó nauðsynlegt að verja Eptifibatide Accord gegn ljósi meðan það er gefið.
English: One vial of 10 ml of solution for injection contains 20 mg of eptifibatide.
Icelandic: Eitt hettuglas með 10 ml af stungulyfi, lausn inniheldur 20 mg af eptifibatíði.
English: - if you have or have had severe hypertension (high blood pressure).
Icelandic: - ef þú ert með eða hefur verið með háþrýsting (of háan blóðþrýsting).
English: Solution for injection.
Icelandic: Lyfseðilsskylt lyf.
English: Cardiac Disorders
Icelandic: MEÐ BLINDRALETRI
English: The recommended dosage is an intravenous bolus of 180 microgram/kg administered as soon as possible following diagnosis, followed by a continuous infusion of 2 microgram/kg/min for up to 72 hours, until initiation of coronary artery bypass graft (CABG) surgery, or until discharge from the hospital (whichever occurs first).
Icelandic: Ráðlagður hleðsluskammtur er 180 míkróg/kg líkamsþunga gefin í bláæð eins fljótt og unnt er eftir sjúkdómsgreiningu og fylgt eftir með samfelldu innrennsli af 2 míkróg/kg/mín.
English: Biotransformation
Icelandic: Slagæðaaðgerðir
English: Thrombocytopenia, including acute profound thrombocytopenia, has been observed with eptifibatide administration post-marketing (see section 4.8)
Icelandic: Greint hefur verið frá blóðflagnafæð, þar með talið bráðri alvarlegri blóðflagnafæð við gjöf eptifibatíðs eftir að lyfið kom á markað (sjá kafla 4.8).
English: Anaphylactic reactions.
Icelandic: Bráðaofnæmi.
English: After removal of the introducer sheath, careful haemostasis must be ensured under close observation.
Icelandic: Eftir að æðaleggurinn hefur verið fjarlægður, verður að fylgjast vel með og tryggja að blæðingar stöðvist.
English: Experience in patients with hepatic impairment is very limited.
Icelandic: Mjög takmörkuð reynsla er af notkun lyfsins hjá sjúklingum með skerta lifrarstarfsemi.
English: Eptifibatide and thrombolytic agents
Icelandic: Eptifibatíð og segaleysandi lyf
English: - skin rash (such as hives).
Icelandic: - húðútbrot (svo sem ofsakláði).
English: Eptifibatide Accord is an inhibitor of platelet aggregation.
Icelandic: Eptifibatide Accord hindrar samloðun blóðflagna.
English: Shock, hypotension, phlebitis.
Icelandic: Lost, lágþrýstingur, bláæðarbólga.
English: The rate of infusion was 2.0 microgram/kg/min for patients with serum creatinine ≤ 175 micromols/l or 1.0 microgram/kg/min for serum creatinine > 175 up to 350 micromols/l.
Icelandic: fyrir sjúklinga sem voru með kreatínín í sermi ≤ 175 míkrómól/l, eða 1 míkróg/kg/mín.
English: Eptifibatide Accord inhibits platelet aggregation, but does not appear to affect the viability of platelets.
Icelandic: Blóðflagnafæð og ónæmissvörun tengd GP IIb/IIIa-hemlum Eptifibatide Accord hindrar samloðun blóðflagna, en virðist ekki hafa áhrif á líftíma þeirra.
English: Medicinal product subject to medical prescription.
Icelandic: Skammtur lyfsins fer eftir líkamsþyngd sjúklings.
English: Eptifibatide Accord 2 mg/ml solution for injection: 10 ml vial, pack of one vial.
Icelandic: Eptifibatide Accord 2 mg/ml stungulyf, lausn.
English: - If you have any further questions, ask your doctor or hospital pharmacist or nurse.
Icelandic: - Leitið til læknisins eða sjúkrahúslyfjafræðings eða hjúkrunarfræðings ef þörf er á frekari upplýsingum.
English: Table 1: Incidence of Death/CEC-Assessed MI («Treated as Randomised» Population)
Icelandic: Dánartíðni/CEC-metið hjartadrep (slembiúrtaksrannsókn)
English: Do not use if particulate matter or discolouration is present.
Icelandic: Ekki má nota lyfið ef einhverjar agnir eru í því eða litabreytingar hafa orðið.
English: PURSUIT trial The pivotal clinical trial for Unstable Angina (UA)/Non-Q Wave Myocardial Infarction (NQMI) was PURSUIT.
Icelandic: PURSUIT-rannsóknin er mjög mikilvæg rannsókn á hvikulli hjartaöng (UA) og hjartadrepi án Qbylgju (NQMI).
English: 0.25 mg Powder for concentrate for solution for infusion
Icelandic: 0,25 mg stofn fyrir innrennslisþykkni, lausn